Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinigen to acquire US rights to Novartis cancer drug Proleukin
Proleukin is approved in the US for the treatment of metastatic melanoma and metastatic renal cell carcinoma. As per the terms, Clinigen will make an initial payment of
Proleukin is approved in the US for the treatment of metastatic melanoma and metastatic renal cell carcinoma. As per the terms, Clinigen will make an initial payment of
Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed. LEXETTE is part of the US$600m potent topical corticosteroid
This collaboration underscores Boehringer Ingelheim’s commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada. Based
The company said that new data from three independent preclinical animal models of lung, kidney and liver fibrosis have yielded promising preclinical efficacy data for its ROCK2 compound.
B-cell maturation antigen (BCMA) has emerged as an attractive target for multiple myeloma therapeutics. TNB-383B is a bispecific antibody that simultaneously targets BCMA and CD3, utilizing Teneobio’s unique
The new company will focus on the development of a novel family of small molecule inhibitors designed to block tumor growth and stimulate the immune system to fight
Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as
The contract from the Small Business Research Initiative (“SBRI”), administered by Innovate UK, will be used to make the Company’s epidermicin NI01 antibiotic ready for phase 1 human
MEDI8897, which is a single dose extended half-life anti-RSV F monoclonal antibody (mAb), is being developed jointly by AstraZeneca’s biologics research and development arm MedImmune and Sanofi Pasteur.
The approval being sought from the US Food and Drug Administration (FDA) is for the post-surgery use of Kadcyla in patients with HER2-positive early breast cancer with residual